Fosfato de Calcio PDF

Mobile Help FAQs TOXNET Fact Sheet Training Manual & Schedule
TOXNET Home > Multi-database Search Results > Full Record
HSDB: CALCIUM HYDROGEN PHOSPHATE CASRN: 7757-93-9 This record appears in multiple databases.
View record in another database: HSDB Download this Record Print Select Record My List Permalink
Recent related PubMed toxicology articles
TABLE OF CONTENTS
CALCIUM HYDROGEN PHOSPHATE
Expand all
Show Selected Items Clear CASRN: 7757-93-9
Collapse all
UNII: L11K75P92J
Closest Match to Search Terms
Reviewed by SRP on 1/31/1999
Full Record
Human Health Effects

Emergency Medical Treatment
Metabolism/ Pharmacokinetics
Pharmacology
Environmental Fate & Exposure
FULL RECORD DISPLAY
Environmental Standards &
Regulations Displays all fields in the record.
Chemical/Physical Properties For other data, click on the Table of Contents

Chemical Safety & Handling
Manufacturing/Use Information
Laboratory Methods Human Health Effects:
Special References
Synonyms and Identifiers
Skin, Eye and Respiratory Irritations:
Administrative Information Skin and eye irritant.
[Lewis, R.J. Sax's Dangerous Properties of Industrial Materials. 9th ed. Volumes 1-3. New York, NY: Van Nostrand
Show Selected Items Clear Reinhold, 1996., p. 637] **PEER REVIEWED**
Drug Warnings:
BECAUSE OF PHOSPHATE CONTENT, IT IS CONTRAINDICATED IN /PERSONS WITH/

HYPOPARATHYROIDISM.
[Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack
Publishing Co., 1975., p. 770] **PEER REVIEWED**
Emergency Medical Treatment:

Emergency Medical Treatment:
EMT Copyright Disclaimer:
The information contained in the Truven Health Analytics Inc. products is intended as an educational aid only. All
treatments or procedures are intended to serve as an information resource for physicians or other competent
healthcare professionals performing the consultation or evaluation of patients and must be interpreted in view of all
attendant circumstances, indications and contraindications. The use of the Truven Health Analytics Inc. products is at
your sole risk. These products are provided "as is" and "as available" for use, without warranties of any kind, either
express or implied. Truven Health Analytics Inc. makes no representation or warranty as to the accuracy, reliability,
timeliness, usefulness or completeness of any of the information contained in the products. Additionally, Truven
Health ANALYTICS INC. makes no representation or warranties as to the opinions or other service or data you may
access, download or use as a result of use of the Truven Health ANALYTICS INC. products. All implied warranties of
merchantability and fitness for a particular purpose or use are hereby excluded. Truven Health Analytics Inc. does
not assume any responsibility or risk for your use of the Truven Health Analytics Inc. products.
The following Overview, *** CALCIUM SALTS ***, is relevant for this HSDB record chemical.
Life Support:
o This overview assumes that basic life support measures

have been instituted.
Clinical Effects:
0.2.1 SUMMARY OF EXPOSURE

0.2.1.1 ACUTE EXPOSURE
A) USES: Calcium carbonate is used medically as an
antacid. Calcium citrate and calcium carbonate are used
as dietary supplements. Calcium chloride and gluconate
are used medically for treatment of hypocalcemia,
hyperkalemia, and hypermagnesemia. Calcium salts are
used in manufacturing, mining and other industries.
B) PHARMACOLOGY: Calcium is a cation that is necessary for
many physiological activities, some of which are poorly
understood. It is essential for the normal functioning
of organ systems including the muscles, nervous system,
and cardiac function.
C) TOXICOLOGY: Hypercalcemia may cause abdominal pain,
delirium and renal stones. Prolonged ingestion of
alkaline calcium salts may cause metabolic alkalosis
and hypercalcemia (the "milk-alkali syndrome").
D) EPIDEMIOLOGY: Exposure to calcium containing antacids
is common, but significant toxicity is very rare.
E) WITH THERAPEUTIC USE
1) ADVERSE EFFECTS: Calcium supplements may cause GI
upset or constipation. Patients with renal
insufficiency may develop hypercalcemia. Extravasation
of calcium chloride salts may cause local irritation
or necrosis. Rapid intravenous administration of
calcium salts may cause hypotension, bradycardia,
syncope, and cardiac dysrhythmias.
F) WITH POISONING/EXPOSURE
1) MILD TO MODERATE TOXICITY: Acute calcium poisoning is
rare, and almost exclusively from intravenous
administration. Symptoms of hypercalcemia include
lethargy, muscle weakness, vomiting, nausea and
constipation. Some calcium salts cause
gastrointestinal irritation. Minor skin exposure to
caustic calcium salts may cause dermal irritation.
2) SEVERE TOXICITY: Life threatening manifestations are
very rare and include complications from altered
mental status such as aspiration pneumonia, and
cardiac dysrhythmias.
0.2.20 REPRODUCTIVE HAZARDS
A) Calcium is classified as FDA pregnancy category C. There
are no adequate and well-controlled studies of calcium
use in pregnant women. The teratogenic risk associated
with a normal calcium concentration in the blood appears
to be minimal. A case report described milk-alkali
syndrome in a pregnant woman who ingested large
quantities of calcium carbonate, milk, and cheese for
hyperemesis. A stillborn fetus with short limbs, low-set
ears, normal chromosomes, and lack of evidence of tissue
calcification was delivered at week 37 gestation.
Calcium is secreted in breast milk in significant
amounts; infant harm is not expected if the maternal
calcium levels are maintained within the normal range.
Laboratory:
A) Following an inadvertent exposure, an asymptomatic

patient does not require routine testing, unless the
ingestion was very large.
B) A patients with a massive ingestion and being treated
with IV hydration should have baseline renal function
testing and hourly serum calcium determinations.
C) If milk-alkali syndrome is suspected, serum electrolytes
(including calcium and phosphorus), serum pH and renal
function should be measured.
Treatment Overview:
0.4.2 ORAL EXPOSURE

A) MANAGEMENT OF MILD TO MODERATE TOXICITY
1) There is no specific antidote for calcium salts
poisoning. Most cases of hypercalcemia can be treated
with saline hydration. Gastrointestinal or skin
irritation is usually self-limited and does not require
specific treatment beyond decontamination. There is no
role for bisphosphonates or calcitonin in the treatment
of hypercalcemia due to calcium salt exposure.
B) MANAGEMENT OF SEVERE TOXICITY
1) Most cases of hypercalcemia will resolve with hydration
in patients with normal renal function. Hemodialysis
can be used if emergent clearance is required of if the
patient's renal function is impaired. There is no role
for bisphosphonates or calcitonin in the treatment of
hypercalcemia due to calcium salt exposure.
C) DECONTAMINATION
1) PREHOSPITAL: DERMAL EXPOSURE: Remove clothes and wash
the body with copious amounts of water following dermal
exposure to caustic salts.
2) HOSPITAL: Gastric decontamination is not indicated for
ingestion of salts. Patients who ingest caustic salts
should rinse their mouth and may ingest a small amount
(30 to 60 mL) of water.
D) ANTIDOTE
1) There is no antidote for calcium salts.
E) EXTRAVASATION INJURY
1) If extravasation occurs, stop the infusion. Disconnect
the IV tubing, but leave the cannula or needle in
place. Attempt to aspirate the extravasated drug from
the needle or cannula. If possible, withdraw 3 to 5 mL
of blood and/or fluids through the needle/cannula.
Administer hyaluronidase (see below). Elevate the
affected area. Apply warm packs for 15 to 20 minutes at
least 4 times daily. Administer analgesia for severe
pain. If pain persists, there is concern for
compartment syndrome, or injury is apparent, an early
surgical consult should be considered. Close
observation of the extravasated area is suggested. If
tissue sloughing, necrosis or blistering occurs, treat
as a chemical burn (ie, antiseptic dressings, silver
sulfadiazine, antibiotics when applicable). Surgical or
enzymatic debridement may be required. Risk of
infection is increased in chemotherapy patients with
reduced neutrophil count following extravasation.
Consider culturing any open wounds. Monitor the site
for the development of cellulitis, which may require
antibiotic therapy.
F) ENHANCED ELIMINATION PROCEDURE
1) Calcium is rapidly cleared by hemodialysis. However,
dialysis is rarely indicated unless the patient has
renal failure.
G) PATIENT DISPOSITION
1) HOME CRITERIA: A patient who is asymptomatic or has
mild GI irritation after an inadvertent exposure can be
observed at home.
2) OBSERVATION CRITERIA: A symptomatic patient and/or
those with a deliberate overdose should be evaluated in
a healthcare facility.
3) ADMISSION CRITERIA: Patients who have high serum
calcium concentrations that do not improve with
hydration, or have concomitant renal insufficiency,
should be admitted for hydration and monitoring.
Range of Toxicity:
A) TOXIC DOSE: Persons who consume more than 10 g of CaCO3

(= 4 g Ca) are at risk of developing milk-alkali
syndrome, but the condition has been reported in at least
one person consuming only 2.5 g/day of CaCO3 ( =1 g Ca),
an amount usually considered moderate and safe. Patients
with predisposing conditions such as renal insufficiency
may develop the syndrome after chronic ingestion of 5 to
10 g/day CaCO3, and those with dialysis dependent renal
failure can develop hypercalcemia after 3.2 to 6.4 g/day.
Normal total serum calcium concentrations are 9 to 10.4
mg/dL (4.5 to 5.2 mEq/L). Symptoms may appear when plasma
calcium concentrations reach 6.6 mEq/L.
B) THERAPEUTIC DOSE: In cases of hyperkalemia,
hypermagnesemia, or calcium channel blocker overdose,
administer calcium gluconate or chloride: 1 to 2 g IV
titrated to clinical response. In patents with severe
calcium channel blocker overdose, higher doses of calcium
may be needed. Calcium repletion: 1 to 2 g/day of
elemental calcium.
[Rumack BH POISINDEX(R) Information System Micromedex, Inc., Englewood, CO, 2017; CCIS Volume 172,
edition expires May, 2017. Hall AH & Rumack BH (Eds): TOMES(R) Information System Micromedex, Inc.,
Englewood, CO, 2017; CCIS Volume 172, edition expires May, 2017.] **PEER REVIEWED**
Metabolism/ Pharmacokinetics:
Absorption, Distribution & Excretion:
... ITS ELEMENTS ARE SLOWLY ABSORBED FROM SMALL INTESTINE.

[Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 71] **PEER
REVIEWED**
Pharmacology:
Therapeutic Uses:
USES--EXCELLENT SOURCE OF CALCIUM & PHOSPHORUS DURING PREGNANCY, LACTATION, OR MILD TO
MODERATE HYPOCALCEMIA CHARACTERIZED BY LOW DEGREE OF TETANY. ... IF TETANY IS SEVERE, IV
CALCIUM MEDICATION IS ADMIN. ... DOSE--1 TO 5 G/DAY IN 2 OR MORE DIVIDED DOSES.
IT IS NOT MARKETED IN SINGLE ENTITY FORM, SO THAT DOSE OF OTHER INGREDIENTS MAY HAVE TO BE
CONSIDERED IN ARRIVING @ SUITABLE SCHEDULE. CALCIUM IS BETTER ABSORBED IF TAKEN IN SMALL
DOSES @ FREQUENT INTERVALS.
MEDICATION (VET): FOR PREVENTION & TREATMENT OF RICKETS ALONG WITH VITAMIN D THERAPY, & AS
NUTRIENT SOURCE OF CALCIUM & PHOSPHORUS IN FEEDSTUFFS. ... OPTIMUM CALCIUM:PHOSPHORUS
RATIO IN DIET MUST ALSO BE MAINTAINED.
[Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 71] **PEER
REVIEWED**
DIBASIC CALCIUM PHOSPHATE, NATIONAL FORMULARY ... /IS AMONG CMPD/ CLASSIFIED AS
NONSYSTEMIC GASTRIC ANTACIDS, BUT THEIR EFFICACY IS LOW & THEY ARE SELDOM EMPLOYED.
[Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan
Publishing Co., Inc., 1975., p. 967] **PEER REVIEWED**
Medication (VET): Has been used as a dietary supplement, and as an antacid.

[Budavari, S. (ed.). The Merck Index - Encyclopedia of Chemicals, Drugs and Biologicals. Rahway, NJ: Merck and
Co., Inc., 1989., p. 256] **PEER REVIEWED**
Drug Warnings:
BECAUSE OF PHOSPHATE CONTENT, IT IS CONTRAINDICATED IN /PERSONS WITH/
HYPOPARATHYROIDISM.
Environmental Fate & Exposure:

Natural Pollution Sources:
OCCURS IN NATURE AS MINERAL MONETITE.
[Budavari, S. (ed.). The Merck Index - Encyclopedia of Chemicals, Drugs and Biologicals. Rahway, NJ: Merck and
Co., Inc., 1989., p. 256] **PEER REVIEWED**
Environmental Standards & Regulations:

FIFRA Requirements:
Residues of calcium phosphate are exempted from the requirement of a tolerance when used as a solid diluent or
carrier in accordance with good agricultural practices as inert (or occasionally active) ingredients in pesticide
formulations applied to growing crops or to raw agricultural commodities after harvest. /Calcium phosphate/
[40 CFR 180.1001(c) (7/1/97)] **PEER REVIEWED**
Acceptable Daily Intakes:
FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES...RECOMMENDED.../LEVELS/ FOR TOTAL DIETARY

PHOSPHORUS...UNCONDITIONAL ACCEPTANCE LEVEL /OF LESS THAN 30 MG/KG BODY WT/ IS
CONSIDERED SAFE IN ANY TYPE OF DIET...CONDITIONAL ACCEPTANCE LEVEL /OF 30-70 MG/KG BODY WT/
IS ACCEPTABLE ONLY WHEN DIETARY CALCIUM LEVEL IS HIGH /PHOSPHATES/
[Furia, T.E. (ed.). CRC Handbook of Food Additives. 2nd ed. Cleveland: The Chemical Rubber Co., 1972., p. 641]
**PEER REVIEWED**
FDA Requirements:
Substances classified as stabilizers, when migrating from food-packaging material shall incl ... calcium hydrogen
phosphate.
[21 CFR 181.29 (4/1/97)] **PEER REVIEWED**
Calcium phosphate (mono-, di-, and tribasic) used as a multiple purpose GRAS food substance in food for human
consumption is generally recognized as safe when used in accordance with good manufacturing practice. /Calcium
phosphate (mono-, di-, and tribasic)/
[21 CFR 182.1217 (4/1/97] **PEER REVIEWED**
Calcium phosphate (mono-, di-, and tribasic) used as a nutrient in food for human consumption is generally
recognized as safe when used in accordance with good manufacturing practice. /Calcium phosphate (mono-, di-,
and tribasic)/
Calcium phosphate (mono-, di-, and tribasic) used as a general purpose food additive in animal drugs, feeds, and
related products is generally recognized as safe when used in accordance with good manufacturing or feeding
practice. /Calcium phosphate (mono-, di-, and tribasic)/
Calcium phosphate (mono-, di-, andtribasic) used as a nutrient and/or dietary supplement in animal drugs, feeds,
and related products is generally recognized as safe when used in accordance with good manufacturing or feeding
practice. /Calcium phosphate (mono-, di-, and tribasic)/
Allowable Tolerances:
Residues of calcium phosphate are exempted from the requirement of a tolerance when used as a solid diluent or
carrier in accordance with good agricultural practices as inert (or occasionally active) ingredients in pesticide
formulations applied to growing crops or to raw agricultural commodities after harvest. /Calcium phosphate/
[40 CFR 180.1001(c) (7/1/97)] **PEER REVIEWED**
Chemical/Physical Properties:
Molecular Formula:
CA.H3-O4-P
**PEER REVIEWED**
Molecular Weight:
136.06
[Budavari, S. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station,
NJ: Merck and Co., Inc., 1996., p. 276] **PEER REVIEWED**
Color/Form:
Triclinic crystals
White crystalline powder

[Lewis, R.J., Sr (Ed.). Hawley's Condensed Chemical Dictionary. 12th ed. New York, NY: Van Nostrand Rheinhold
Co., 1993, p. 206] **PEER REVIEWED**
Odor:
Odorless
Taste:
Tasteless
Density/Specific Gravity:
2.89
[Gerhartz, W. (exec ed.). Ullmann's Encyclopedia of Industrial Chemistry. 5th ed.Vol A1: Deerfield Beach, FL: VCH
Publishers, 1985 to Present., p. VA19 498] **PEER REVIEWED**
Solubilities:
Practically insol in water, alc

Sol in dil hydrochloric, nitric & acetic acids

Other Chemical/Physical Properties:

At red heat dehydrated to calcium pyrophosphate
Loses water @ 109 deg C /hydrate/

Monoclinic crystals; density: 2.31 /Calcium hydrogen phosphate dihydrate, brushite/

Index of refraction = 1.5576, 1.5457, 1.5392 /Calcium hydrogen phosphate dihydrate/

[Lide, D.R. (ed). CRC Handbook of Chemistry and Physics. 72nd ed. Boca Raton, FL: CRC Press, 1991-1992., p. 4-
49] **PEER REVIEWED**
Solubility: cold water 0.0316 g/100 cc @ 38 deg C; hot water 0.075 g/100 cc @ 100 deg C /Calcium hydrogen
phosphate dihydrate/
[Lide, D.R. (ed). CRC Handbook of Chemistry and Physics. 72nd ed. Boca Raton, FL: CRC Press, 1991-1992., p. 4-
Slowly converted to the anhydrous salt at 36 deg C. Dissolves in water with precipitation of the hydroxyapitite,
Ca5(PO4)3OH, and formation of an aqueous phase with increasing P2O5 content. /Dihydrate/
Publishers, 1985 to Present., p. VA 19 498] **PEER REVIEWED**
Chemical Safety & Handling:

Skin, Eye and Respiratory Irritations:
Skin and eye irritant.
[Lewis, R.J. Sax's Dangerous Properties of Industrial Materials. 9th ed. Volumes 1-3. New York, NY: Van Nostrand
Reinhold, 1996., p. 637] **PEER REVIEWED**
Fire Potential:
NONFLAMMABLE.
[Sax, N.I. and R.J. Lewis, Sr. (eds.). Hawley's Condensed Chemical Dictionary. 11th ed. New York: Van Nostrand
Reinhold Co., 1987., p. 207] **PEER REVIEWED**
Preventive Measures:
SRP: The scientific literature for the use of contact lenses in industry is conflicting. The benefit or detrimental effects of
wearing contact lenses depend not only upon the substance, but also on factors including the form of the substance,
characteristics and duration of the exposure, the uses of other eye protection equipment, and the hygiene of the
lenses. However, there may be individual substances whose irritating or corrosive properties are such that the wearing
of contact lenses would be harmful to the eye. In those specific cases, contact lenses should not be worn. In any
event, the usual eye protection equipment should be worn even when contact lenses are in place.
**PEER REVIEWED**
Stability/Shelf Life:
STABLE IN AIR
Disposal Methods:
SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to
significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with
environmental regulatory agencies for guidance on acceptable disposal practices.
**PEER REVIEWED**
Manufacturing/Use Information:
View products that contain this chemical: CALCIUM HYDROGEN PHOSPHATE
Uses:
Control acidity in powdered drink mixes, ingredient in effervescent tablets, as a plastics stabilizer, and in ceramics. Its
single largest application is as a leavening agent in bread, cake mixes, and self-rising flour.
[Kirk-Othmer Encyclopedia of Chemical Technology. 4th ed. Volumes 1: New York, NY. John Wiley and Sons, 1991-
Present., p. V18 693] **PEER REVIEWED**
Chiefly in animal feeds; mineral supplement in cereals and other foods; manuf of glass; in dental products, fertilizers.
THERAP CAT: Calcium replenisher.

THERAP CAT (VET): Has been used as a dietary supplement, and as an antacid.
Pellitizing aid and thickening agent in the pharmaceutical industry. Use as a fertizer component for tropical soils.
Publishers, 1985 to Present., p. VA19 499] **PEER REVIEWED**
Manufacturers:
B & B Specialties Inc., 1104 South Monroe, Spencer, WI 54479 (715) 659-4638
[SRI. 1997 Directory of Chemical Producers -United States of America. Menlo Park, CA: SRI International 1997., p.
Cargill Fertilizer, Inc., 8813 Hwy. 41 South, Riverview, FL 33569 (813) 671-6146
FMC Corporation, Chemical Products Group, Phosphorus Chemicals Division, Hq, 200 East Randolph Drive, Chicago,
IL 60601 (312) 861-6000. Production site: Buffalo, NY 14240
Monsanto Company, Chemical Group, Hq, 800 North Lindbergh Boulevard, St. Louis, MO 63167, (314) 694-1000.
Production site: Carondelet, MO 63111
Rhone-Poulenc Inc., Chemical Sector, Hq, CN 5266, Princeton, NJ 08543-5266, (908) 297-1597. Production sites:
Chicago Heights, IL 60411; Nashville, TN 37202
Methods of Manufacturing:
... From calcium chloride & disodium phosphate; from tricalcium phosphate & phosphoric acid; where it is
intermediate in prepn of hydroxyapatite.
Interaction of fluorine-free phosphoric acid with milk of lime.

General Manufacturing Information:

... CAN INACTIVATE METALLIC IONS, WHICH ARE CAPABLE OF INTERFERING WITH NECESSARY FOOD-
PROCESSING REACTIONS ... /INACTIVATION IS/ EITHER BY PPTN & REMOVING THEM FROM
INTERFERENCE WITH DESIRED FOOD-PROCESSING REACTIONS OR BY COMPLEXING & MAINTAINING
THEM IN SOL, BOUND STATE. /PHOSPHATES/
[Furia, T.E. (ed.). CRC Handbook of Food Additives. 2nd ed. Cleveland: The Chemical Rubber Co., 1972., p. 644]
**PEER REVIEWED**
Because calcium hydrogen phosphate is incongruently soluble, it is typically contaminated with various amounts (6-
10%) of dicalcium phosphate and free phosphorus acid resulting from in-process disproportionation of the
monocalcium salt.
Since phosphorus acid impurity may render the product hygroscopic and absorbed water and acid catalyzes further
disproportionation, excess lime may be added to industrial monocalcium phosphate to ensure removal of residual free
phosphoric acid. Therefore the product may contain dicalcium phosphate.
... The hygroscopic nature of anhydrous monocalcium phosphate limited its commercial applications. However, the
addition of small amounts of potassium (+1), sodium (+1), and aluminum (+3) ions to the crystallization mother liquor
... results ... glassy coating protects the calcium phosphate from moisture and greatly improves its handling
properties and performance in several applications ...
Present., p. V18 691-3] **PEER REVIEWED**
Formulations/Preparations:
GRADES: United States Pharmacopeia; "Food Chemicals Codex"; Dentrifice grade; Feed grade, 18.5 or 21%
phosphorus.
DOSAGE FORMS: CALCIUM PHOSPHATE & VITAMIN D (SQUIBB): EACH TABLET CONTAINS DIBASIC
CALCIUM PHOSPHATE 228 MG, CALCIUM CARBONATE 45 MG, & VITAMIN D 330 IU.
[American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts:
PSG Publishing Co., Inc., 1977., p. 262] **PEER REVIEWED**
Anhydrous and monohydrate salt

Impurities:
Dicalcium phosphate, phosphoric acid.

Laboratory Methods:
Sampling Procedures:
NIOSH Method 7300. Analyte: Phosphorus. Matrix: Air. Sampler: Filter (0.8 um, cellulose ester membrane). Flow
Rate: 1 to 4 l/min. Sample Size: 500 liters. Shipment: Routine. Sample Stability: Stable. /Phosphorus/
[U.S. Department of Health and Human Services, Public Health Service. Centers for Disease Control, National
Institute for Occupational Safety and Health. NIOSH Manual of Analytical Methods, 3rd ed. Volumes 1 and 2 with
1985 supplement, and revisions. Washington, DC: U.S. Government Printing Office, February 1984., p. 7300-1]
**PEER REVIEWED**
Special References:
Special Reports:
Optimal Calcium Uptake. Current Bibliographies in Medicine 94-4. Public Services Division/National Library of
Medicine. 775 citations from January, 1990-April, 1994. Available from:
http://www.nlm.nih.gov/pubs/cbm/calcium.htmlDepartment of Health and Human Services, Public Health Service.
Centers for Disease Control, National Institute for Occupational Safety and Health. NIOSH Manual of Analytical
Methods, 3rd ed. Volumes 1 and 2 with 1985 supplement, and revisions. Washington, DC: U.S. Government Printing
Office, February 1984., p. 7300-1] **PEER REVIEWED** Synonyms and Identifiers:
Synonyms:
CALCIUM ACID PHOSPHATE
**PEER REVIEWED**
CALCIUM DIBASIC PHOSPHATE

**PEER REVIEWED**
CALCIUM HYDROGEN ORTHOPHOSPHATE

**PEER REVIEWED**
CALCIUM MONOHYDROGEN PHOSPHATE

**PEER REVIEWED**
CALCIUM PHOSPHATE (1:1)

**PEER REVIEWED**
CALCIUM PHOSPHATE (CAHPO4)

**PEER REVIEWED**
CALCIUM PHOSPHATE, DIBASIC

**PEER REVIEWED**
CALCIUM SECONDARY PHOSPHATE

**PEER REVIEWED**
MONOCALCIUM ACID PHOSPHATE

**PEER REVIEWED**
MONOCALCIUM ORTHOPHOSPHATE
**PEER REVIEWED**
PHOSPHORIC ACID, CALCIUM SALT (1:1)

**PEER REVIEWED**
SECONDARY CALCIUM PHOSPHATE

**PEER REVIEWED**
Associated Chemicals:
Calcium hydrogen phosphate hydrate;15634-16-9
Calcium hydrogen phosphate dihydrate;7789-77-7
Formulations/Preparations:
GRADES: United States Pharmacopeia; "Food Chemicals Codex"; Dentrifice grade; Feed grade, 18.5 or 21%
phosphorus.
DOSAGE FORMS: CALCIUM PHOSPHATE & VITAMIN D (SQUIBB): EACH TABLET CONTAINS DIBASIC
CALCIUM PHOSPHATE 228 MG, CALCIUM CARBONATE 45 MG, & VITAMIN D 330 IU.
[American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts:
PSG Publishing Co., Inc., 1977., p. 262] **PEER REVIEWED**
Anhydrous and monohydrate salt

Administrative Information:
Hazardous Substances Databank Number:
992
Last Review Date:

Reviewed by SRP on 1/31/1999
Last Revision Date:

20030305
Update History:
Complete Update on 03/05/2003, 1 field added/edited/deleted.
Field Update on 08/06/2002, 1 field added/edited/deleted.
Complete Update on 04/28/1999, 26 fields added/edited/deleted.
Field Update on 03/21/1994, 1 field added/edited/deleted.
Field update on 12/17/1992, 1 field added/edited/deleted.
Field update on 12/29/1989, 1 field added/edited/deleted.
Complete Update on 12/21/1984
U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894

About Contact Us SIS Home Copyright Privacy Accessibility Viewers and Players
National Institutes of Health, Health & Human Services

Fosfato de Calcio PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Fosfato de Calcio PDF

Uploaded by

Copyright:

Available Formats

Mobile Help FAQs TOXNET Fact Sheet Training Manual & Schedule

TOXNET Home > Multi-database Search Results > Full Record

Recent related PubMed toxicology articles

Human Health Effects

Chemical/Physical Properties For other data, click on the Table of Contents

Show Selected Items Clear Reinhold, 1996., p. 637] **PEER REVIEWED**

BECAUSE OF PHOSPHATE CONTENT, IT IS CONTRAINDICATED IN /PERSONS WITH/

Emergency Medical Treatment:

EMT Copyright Disclaimer:

o This overview assumes that basic life support measures

0.2.1 SUMMARY OF EXPOSURE

A) Following an inadvertent exposure, an asymptomatic

0.4.2 ORAL EXPOSURE

A) TOXIC DOSE: Persons who consume more than 10 g of CaCO3

... ITS ELEMENTS ARE SLOWLY ABSORBED FROM SMALL INTESTINE.

Medication (VET): Has been used as a dietary supplement, and as an antacid.

Environmental Fate & Exposure:

Environmental Standards & Regulations:

Acceptable Daily Intakes:

FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES...RECOMMENDED.../LEVELS/ FOR TOTAL DIETARY

White crystalline powder

Practically insol in water, alc

Sol in dil hydrochloric, nitric & acetic acids

Other Chemical/Physical Properties:

Loses water @ 109 deg C /hydrate/

Monoclinic crystals; density: 2.31 /Calcium hydrogen phosphate dihydrate, brushite/

Index of refraction = 1.5576, 1.5457, 1.5392 /Calcium hydrogen phosphate dihydrate/

Chemical Safety & Handling:

THERAP CAT: Calcium replenisher.

Interaction of fluorine-free phosphoric acid with milk of lime.

General Manufacturing Information:

Anhydrous and monohydrate salt

Dicalcium phosphate, phosphoric acid.

CALCIUM DIBASIC PHOSPHATE

CALCIUM HYDROGEN ORTHOPHOSPHATE

CALCIUM MONOHYDROGEN PHOSPHATE

CALCIUM PHOSPHATE (1:1)

CALCIUM PHOSPHATE (CAHPO4)

CALCIUM PHOSPHATE, DIBASIC

CALCIUM SECONDARY PHOSPHATE

MONOCALCIUM ACID PHOSPHATE

PHOSPHORIC ACID, CALCIUM SALT (1:1)

SECONDARY CALCIUM PHOSPHATE

Anhydrous and monohydrate salt

Last Review Date:

Last Revision Date:

U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894

You might also like

Show Selected Items Clear Reinhold, 1996., p. 637] PEER REVIEWED